Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept trial of oral bromelain in COVID-19 positive patients
2020-005523-37Phase 2Terminated
- Sponsor
- URSAPHARM
- Start
- Apr 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of bromelain in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by URSAPHARM. Primary endpoint: Baseline-adjusted course of median symptom score (day 1–day 11). Started Apr 2021; status: terminated.
02
Drugs
bromelain
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005523-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005523-37.